FREQUENTLY Asked Questions

What is the FDA’s policy regarding charging for investigational drugs and biologics?

View All FAQs
About the Author
Proxima CRO Team
Ellie Reynolds, MBE
Regulatory Affairs Manager
Ellie has a Masters in Bioengineering, with a focus in Global Medical Innovation, from Rice University and has worked on multiple medical devices from need identification through the entire development process.

On August 13, 2009, FDA issued 21 CFR Part 312 and 316 Charging for Investigational Drugs Under an Investigational New Drug Application; Expanded Access to Investigational Drugs for Treatment Use; Final Rules. These rules address clinical studies conducted under an IND as well as treatment protocols and treatment INDs. Part 312 discusses regular INDs while Part 316 discusses the regulations surrounding orphan drug applications.

Related FAQs:
More Questions? We're here to help!
SPEAK WITH A SPECIALIST